Vaccine news has created big opportunity.
Look at BioNTech for example. The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had a 95% effective rate with no safety concerns.
“Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,”Pfizer and BioNTech said, as quoted by CNN.
Now, the two are waiting to hear from the US FDA on emergency use authorization.
“Depending on how fast this [review] is really accomplished, we might get an authorization, or conditional approval already in 2020 which might help us start distribution of the first vaccine batches already in 2020,” said BioNTech CEO Ugur Sahin.
Or look at Moderna (MRNA), which just ran from $79 to $152.74 on news its vaccine is 94% effective, and on news it plans to seek US FDA emergency clearance.
“This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death,” Moderna CEO Stephane Bancel said.
The last time we highlighted MRNA as an opportunity, it traded at $72 on Oct. 20.
The news couldn’t come at a better time.
Last checked, the world was up to 63.3 million cases, with 1.47 million deaths. The U.S. is up to 13.5 million cases. India is up to 9.4 million. Brazil is at 6.3 million. Russia is up to 2.3 million. France is up to 2.27 million. And Spain is just over 1.6 million at the moment.
